| Extracts | Effective doses | Model of study | Effects | References |
| Hydroethanolic | 160 µg/ml | Lymphocyte | ↓ IL-4, IL-10, and NO production | [54] | Aqueous | 100 µg/ml | Vascular endothelial cells | ↓ mRNA expressions of MCP-1 and IL-8 | [55] | Ethanol | 200 µg/ml | RAW 264.7 cells | ↓ TNF-α, IL-1β, and IL-6 | [98] | POL-P3b | 250 µg/ml | DCs | ↑ IL-12, TNF-α, and IL-10 | [57] | Ethanol | 0.5 and 1 mg/ml | RAW 264.7 cells | ↓ NO production and mRNA expression of TNF-α and IL-1-β | [58] | Aqueous | 1–200 μg/ml | HUVECs | ↓ TNF-α-induced overexpression of ICAM-1, VCAM-1, and E-selectin | [55] | Hydroalcoholic | 100 μg/ml | PBMCs | ↓ TNF-α and IL-6 | [59] | Polysaccharide | 600 µg/ml | Rat | ↑ T lymphocytes and B lymphocytes | [60] | Hydroethanolic | 1, 2, and 4 mg/ml | Rat | ↓ TP, PLA2, and IgE | [62] | Hydroethanolic | 1, 2, and 4 mg/ml | Rat | ↓ Serum levels of NO2, NO3, and total WBC count | [63] | Hydroalcoholic | 50, 100, and 200 mg/kg | Rat | ↓ IL-1β, IL-6, TNF-α, PGE2, and TGF-β | [64] | ↑ IL-10 | Aqueous | 300 mg/kg/day | Mice | ↓ NF-κB p65 activation | [65] | ↑ Expression of TGF-β1 and ICAM-1 | Aqueous | 300 mg/kg/day | Mice | ↓ Overexpression of VCAM-1, ICAM-1, E-selectin, MMP-2, and ET-1 | [66] | Hydroalcoholic | 100 and 200 mg/kg | Rat | ↓ Pain-related behaviors and contents of TNF-α and IL1β | [68] | Hydroalcoholic | 400 mg/kg | Rat | ↓ Level of TNF-α | [69] | ↑ Improved memory | Methanolic | 500 mg/kg | Rat | ↓ TNF-α and TGF-β | [70] | Aqueous | 1, 2, and 4 g/kg | Mice | ↓ TNF-α, IL-1b, and IL-6 | [71] | Aqueous | 400 mg/kg/day | Mice | ↓ TNF-α, IL1β, and NF-κB | [72] | Purslane powder | 8% purslane + 100 mg/l CdCl2 in water | Mice | ↓ TNF-α, IL-6, IL-1β, and IFN-γ | [73] | Hydroethanolic | 100 and 300 mg/kg/day | Rat | Improved MDA, TNF-α, and TGF-β1 | [74] | Aqueous and ultrasound-assisted ethanol | 3 mL 1 g/mL | Mice | Inhibited TNF-α, IFN-γ and IL-4 | [75] | Hydroethanolic | 100 and 300 mg/kg/day | Rat | ↓ IL-6, TNF-α, and IL-1β | [76] | ↑ IL-10 | ALA | 125 μM | HCE cells | ↓ Protein and mRNA levels of IL-6, IL-8, IL-1β, and TNF-α | [80] | ALA | 100 μM | THP-1 cells | ↓ Secretion and mRNA levels of IL-6, IL-1β, and TNFα. ALA | [81] | ALA | 5 and 10 mg/kg | RAW 264.7 cells | ↓ Production of NO. and inhibited iNOS, COX-2, and TNF-α gene expressions induced by LPS | [82] | ALA | 6.5% of energy | PBMCs of patients | ↓ Production of IL-6, IL-1β, and TNF-α | [83] | ALA | 60 mg/kg | Mice | Suppressed NF-κB and IL-1β | [84] | ALA | 10% ALA | Mice | ↓ IL-1β, IL-6, and TNFα | [85] | ALA | 500 and 2000 mg/kg | Mice | ↓ IL-6 and IL-1β in nasal mucosa | [86] | ALA | 8 g | Human | ↓ C-reactive protein (CRP), serum amyloid A (SAA), and IL-6 levels | [87] | Quercetin | 100 µg/ml | DCs | ↓ IL-1α, IL-1 β, IL-6, IL-10, IL-12 p70), and chemokines (MCP-1, MIP-1 a, and MIP-1 b) | [89] | Quercetin | 40 µM | Th cells | ↓ IL-2, IFN-γ, and IL-2Ra expressions | [90] | Quercetin | 10, 25 and 50 µM | PBMC | ↓ IL-4 | [91] | ↑ IFN-γ | Quercetin | 50 µM | PBMC | ↓ IL-1β, TNF-α, MMP-9, and TIMP-1 | [92] | Quercetin | 50 µM | BMDM | ↓ iNOS expression, TNF-α, IL-1β protein expression, and IkB-α phosphorylation | [94] | Quercetin | 10–30 μmol/L | HUVEC | ↓ NFκB and expression of VCAM-1 and E-selectin | [93] | Quercetin | 0.1%, w/w | Mice | ↓ IL-1R, CCL8, IKK, serum amyloid A, and fibrinogen | [93] | Quercetin | 1 mg/kg/ | Rat | ↓ TNF-α, IL-1β expression, and iNOS | [94] | Quercetin | 1 mg/kg | Mice | ↓ IL-4, IL-5 secretion, mRNA expression of MMP-9, and EPO | [95] | ↑ IFN-γ | Quercetin | 1500 mg/day, p.o. | Human | ↓ IL-6 and ICAM-1 | [96] | ↑ IL-10 | Quercetin | 50 mg/kg | Mice | ↓ Th17 cells and gut inflammation | [97] | ↑ Treg cells |
|
|